Increasing FLT3-ITD length increases expression of bcl-xl in AML.

被引：0
|
作者：
Seedhouse, Claire H. [1 ]
Pallis, Monica [1 ]
Grundy, Martin [1 ]
Russell, Nigel [1 ]
机构：
[1] Univ Nottingham Hosp, City Hosp Campus, Clin Sci Building, Nottingham NG7 2UH, England
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.1909.1909
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1909
引用
收藏
页码：541A / 541A
页数：1
相关论文
共 50 条
  • [1] SRC Is a Critical Signaling Mediator in FLT3-ITD Positive AML.
    Leischner, Hannes
    Grundler, Rebekka
    Albers, Corinna
    Illert, Anna Lena
    Spickermann, Karsten
    Peschel, Christian
    Duyster, Justus
    BLOOD, 2009, 114 (22) : 196 - 197
  • [2] The benefit of treatment with quizartinib and subsequent bridging to HSCT for FLT3-ITD(+) patients with AML.
    Levis, Mark J.
    Martinelli, Giovanni
    Perl, Alexander E.
    Dombret, Herve
    Steffen, Bjoern
    Rousselot, Philippe H.
    Estey, Elihu
    Shah, Neil P.
    Gammon, Guy
    Trone, Denise
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] FLT3-ITD activation mediates resistance to the BCL-2 selective antagonist, venetoclax, in FLT3-ITD mutant AML models
    Mali, Raghuveer
    Lasater, Elisabeth A.
    Doyle, Kelly
    Malla, Ritu
    Boghaert, Erwin
    Souers, Andrew
    Leverson, Joel
    Sampath, Deepak
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [4] FLT3-ITD Activation Mediates Resistance to the BCL-2 Selective Antagonist, Venetoclax, in FLT3-ITD Mutant AML Models
    Mali, Raghuveer Singh
    Lasater, Elisabeth A.
    Doyle, Kelly
    Malla, Ritu
    Boghaert, Erwin
    Souers, Andrew
    Leverson, Joel D.
    Sampath, Deepak
    BLOOD, 2017, 130
  • [5] HYPOXIA REGULATES FLT3-ITD EXPRESSION AND FUNCTION IN AML CELL-LINES HARBOURING A FLT3-ITD MUTATION
    Sironi, S.
    Wagner, M.
    Vasold, J.
    Drolle, H.
    Fiegl, M.
    ANNALS OF HEMATOLOGY, 2013, 92 : S12 - S13
  • [6] The effect of FLT3 gene expression in senescence and telomere length regulation in AML cells with FLT3-ITD mutation
    Hong, Jing Siou
    Yen, Jui Hung
    Wu, Chia Ling
    Chen, Pei Yi
    CANCER SCIENCE, 2025, 116 : 256 - 256
  • [7] Current Approaches to Transplantation for FLT3-ITD AML
    Bradley D. Hunter
    Yi-Bin Chen
    Current Hematologic Malignancy Reports, 2020, 15 : 1 - 8
  • [8] Current Approaches to Transplantation for FLT3-ITD AML
    Hunter, Bradley D.
    Chen, Yi-Bin
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2020, 15 (01) : 1 - 8
  • [9] Sorafenib plus 5-azacytidine (AZA) in older untreated FLT3-ITD mutated AML.
    Ohanian, Maro
    Garcia-Manero, Guillermo
    Levis, Mark J.
    Jabbour, Elias
    Daver, Naval Guastad
    Borthakur, Gautam
    Kadia, Tapan M.
    Brandt, Mark
    Pierce, Sherry
    Burger, Jan Andreas
    Richie, Mary Ann
    Patel, Keyur
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Ravandi, Farhad
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens
    Castano-Bonilla, Tamara
    Alonso-Dominguez, Juan M.
    Barragan, Eva
    Rodriguez-Veiga, Rebeca
    Sargas, Claudia
    Gil, Cristina
    Chillon, Carmen
    Vidriales, Maria B.
    Garcia, Raimundo
    Martinez-Lopez, Joaquin
    Ayala, Rosa
    Larrayoz, Maria J.
    Anguita, Eduardo
    Cuello, Rebeca
    Cantalapiedra, Alberto
    Carrillo, Estrella
    Soria-Saldise, Elena
    Labrador, Jorge
    Recio, Isabel
    Algarra, Lorenzo
    Rodriguez-Medina, Carlos
    Bilbao-Syeiro, Cristina
    Lopez-Lopez, Juan A.
    Serrano, Josefina
    De Cabo, Erik
    Sayas, Maria J.
    Olave, Maria T.
    Sanchez-Garcia, Joaquin
    Mateos, Mamen
    Blas, Carlos
    Lopez-Lorenzo, Jose L.
    Lainez-Gonzalez, Daniel
    Serrano, Juana
    Martinez-Cuadron, David
    Sanz, Miguel A.
    Montesinos, Pau
    SCIENTIFIC REPORTS, 2021, 11 (01)
12345